PRE-IPO STOCK SPOTLIGHT – NEURALINK

Neuralink is no longer a science project. It is transitioning into a vertically integrated neurotechnology platform with early clinical validation, manufacturing scale ambitions, and a credible path toward becoming one of the most important companies of the next decade.

G.L.A INVE$T RESEARCH

PRIVATE MARKET STOCK SPOTLIGHT: NEURALINK

Neuralink is building a high-bandwidth brain-computer interface (BCI) platform designed to connect the human brain directly to machines. Initially focused on restoring function for patients with paralysis, ALS, and neurological disorders, the long-term vision extends into human-AI symbiosis, cognitive enhancement, and direct “telepathic” communication.

• Latest private valuation: ~ $8B–$9B

• Employees: ~300+

• Clinical patients: 25+ implanted (rapidly scaling)

• Stage: Early commercialization / clinical expansion

The Problem Neuralink Solves

Neuralink is attacking one of the largest and most under-addressed problem spaces globally:

• Over 40% of the population suffers from neurological conditions

• Paralysis, ALS, blindness, and dementia remain largely unsolved

• Human communication bandwidth is extremely limited (speech/typing bottleneck)

Neuralink addresses both:

1. Immediate medical needs (restoring function)

2. Long-term human evolution (brain-AI integration)

Example: A fully paralyzed patient can now control a computer and wheelchair purely through thought—regaining independence after years of immobility.

Neuralink — Pioneering Brain Computer Interfaces

Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.

Neuralink • Neuralink

Product & Technology

Neuralink’s core system includes:

• Implantable brain chip (high channel count neural interface)

• Ultra-thin electrode threads inserted into cortex

• Surgical robot for precision implantation

• AI-driven decoding software

• Proprietary chip + packaging (new PCTF polymer enclosure breakthrough)

Recent breakthroughs:

• Trans-dural implantation (no cutting of dura → safer, faster, scalable)

• High-density electrode packaging (massive signal improvement)

• Neural data training for AI models (future moat layer)

• Potential early-stage “telepathic communication” experiments

This is not a single product—it is a full-stack neurotechnology platform.

Founder & Leadership

Elon Musk (Founder)

One of the strongest founder advantages in private markets:

• Tesla → manufacturing + AI + chips

• SpaceX → vertical integration + engineering culture

• xAI → AI models + compute

• Neuralink benefits from all three ecosystems

President DJ Seo emphasizes:

• Vertical integration as core strategy

• Scale-first thinking from Day 1

• LASIK-style surgery ambition (millions per year)

This is classic Musk playbook: build the machine that builds the machine.

Notable Investors

• Founders Fund (Peter Thiel network proximity)

• Sequoia Capital (via ecosystem exposure/interviews)

• High alignment with elite Silicon Valley capital

Neuralink sits inside the highest quality investor/founder network globally.

Business Model & Growth

Current phase: Clinical validation → early scaling

Near-term revenue:

• Medical device + procedure (insured eventually)

• Clinics + surgical platform

Mid-term:

• Software + neural interface platform

• Data + AI-driven diagnostics

Long-term:

• Cognitive enhancement

• Brain-to-brain / brain-to-AI communication

• Potential subscription ecosystem

Growth signals:

• Expanding patient base globally

• New geographies (Canada, UAE trials)

• Manufacturing scaling (Samsung chip partnership)

• Facility expansion (Austin campus, SF, Fremont)

Total Addressable Market (TAM)

This is one of the largest TAMs in history:

• Neurological disorders: $500B+ global impact

• Assistive technologies: $100B+

• Human-computer interface evolution: multi-trillion

• AI-human integration: effectively uncapped

If successful, Neuralink is not a medical device company—it is a new computing platform.

Moat Analysis

Neuralink’s moat is exceptionally strong and multi-layered:

• Hardware complexity (implant + threads + chip)

• Surgical robotics (extremely hard to replicate)

• Data moat (neural datasets → foundation models)

• Vertical integration (design → manufacturing → surgery)

• Regulatory + clinical head start

• Elon Musk ecosystem advantage

The real long-term moat: proprietary brain data + AI models trained on it.

Competitive Landscape

• China (e.g., Neucyber/Nuracle): faster regulatory scaling, lower complexity devices

• Meta: non-invasive brain decoding

• Snap / Apple / Google: AR wearables (lower fidelity)

Private Market Price History (Estimates)

• 2023: ~$5B valuation

• 2024: ~$7B

• 2025: ~$8B–$9B

Path to Exit

Three realistic paths:

1. IPO (most likely)

• Positioned as both medtech + AI platform

• Could command premium multiple

2. Strategic dominance (remain private longer like SpaceX)

• Driven by Musk preference

3. MERGES WITH SPCX/TSLA into 1 conglomerate

THE G.A.U.N.T.L.E.T SCORING SYSTEM

1. Size & Predictability:7/10
   Early revenue, but massive visibility into demand

2. Visionary Founder: 10/10
   Elon Musk is a generational outlier

3. Must-Have Product: 10/10
   Life-changing for patients, eventually essential for humans

4. Hyper Growth + Financial Position: 8/10
   Pre-revenue scale, but positioned for explosive adoption

5. TAM: 10/10
   Arguably one of the largest TAMs ever

6. Moat Strength: 10/10
   Deep tech + data + vertical integration

7. Risk vs Reward:9/10
   High risk, asymmetric upside (trillion-dollar potential)

8. Solving Major Problems: 10/10
   Directly addresses human suffering and cognition

9. Investor Quality: 9/10
   Top-tier networks and capital

10. Wall Street Misunderstanding: 10/10
    Still widely underestimated and misunderstood

Final GAUNTLET Score: 93 / 100- VERY High

G.L.A INVEST Verdict

Neuralink is one of the highest-upside investments in the private market today.

It passes the GAUNTLET with elite scores across nearly every category. The combination of:

• Founder quality

• Market size

• Technical moat

• Early real-world validation

creates a rare asymmetric opportunity.

This is not just a medtech company—it is a foundational layer for the future of human-computer interaction.

The biggest risk is not competition.
It is execution speed vs regulation and public perception.

If Neuralink succeeds, it will not be a $100B company.
It will be a platform measured in trillions.

COACH KYLE’s 2 CENTS: NEURALINK like SPACEX is an Investment that will be handed down to future generations, I view it as a must BUY.